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We read with great interest the recently published study by Drews et al[1]. Authors compared 
transfusion and bleeding outcomes among patients undergoing coronary artery surgery (CAS) 
with respect to preoperative exposure to either prasugrel or clopidogrel[1]. Patients pretreated 
with prasugrel more often needed perioperative platelet transfusions and had a higher rate of 
surgical reexploration due to bleeding complications[1]. Logistic regression revealed that 
preoperative exposure to prasugrel and urgent/emergent surgery were predictors for the 
composite endpoint defined as “need for perioperative platelet transfusion and/or surgical 
reexploration for bleeding complications”[1].  
Study by Drews et al[1] certainly adds to the current knowledge, however some methodological 
considerations should inevitably be addressed. 
The proportion of patients undergoing  urgent/emergent CAS was higher in patients pretreated 
with prasugrel compared with those on clopidogrel pretreatment[1].This may be considered as a 
bias since patient groups were not balanced for “urgent/emergent CAS” parameter, found to be 
predictor of observed clinical endpoints. Therefore, it would be interesting to see if the results 
would remain the same if two groups would be balanced for “urgent/emergent CAS” parameter 
using propensity matching. 
Furthermore, in such a type of studies, clinical endpoints should be carefully defined. In present 
study, patients in “prasugrel” group have had significantly higher rate of reexplorations for 
excessive bleeding[1]. At the same time, “prasugrel” patients have had significantly higher rate of 
platelet concentrate used[1]. Hypothetically, these outcomes should be inversely related in 
optimal hemostatic management protocol, as it is expected that higher rate of platelet concentrate 
used should prevent or at least reduce occurrence of reexploration for bleeding. The role of 
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platelet concentrate transfusion is even more important considering the fact that in present study, 
diffuse bleeding was found in all cases of reoperation for excessive bleeding[1]. Therefore, 
different way in defining clinical endpoints would be desirable. The fact is that the optimal 
definition of perioperative bleeding remains to be challenging issue. However, International 
Initiative for Hemostasis in Cardiac Surgery recently proposed universal, multistage definition of 
perioperative bleeding in cardiac surgery[2]. This definition presents composite endpoint that is 
consisted of all variables relevant for assessment of bleeding outcome and provides grading of 
bleeding severity[2]. In our opinion, this definition should be used for further similar studies as 
does provide the most reliable estimation of the relationship between preoperative exposure to 
different antiplatelet drugs and occurrence of mild, moderate, severe and massive bleeding, 
respectively[2]. Hypothetically, using this approach, further studies could provide better 
understanding of the possible risks of bleeding inherent to antiplatelet drugs, and expected 
severity of bleeding which in turn could advise preferred preoperative antiplatelet discontinuation 
management as well as timing of surgery.  
Finally, when assessing influence of preoperative antiplatelet drugs administration management 
on bleeding and transfusion outcomes[3], objective quantification of platelet activity using point-
of-care devices should inextricably be included into considerations[3] as it may provide more 
clear pharmacodynamic insight. Our working group recently found that platelet ADP activity 
varies widely among patients exposed to clopidogrel, and corresponds to the extent of 
postoperative bleeding[3,4]. The effect of ADP receptor blockers depends on (1) baseline, 
inherent platelet ADP receptor activity, (2) platelet inhibitory response to antiplatelet drug, as 
well as on (3) recovery rate of platelet function after drug discontinuation. The initial magnitude 
of platelet inhibition at discontinuation has been described as an independent predictor of time to 
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recover platelet function[5]. Patients experiencing “on clopidogrel” pronounced platelet 
inhibition may have the same risk for bleeding as the patients exposed to more potent drug such 
as prasugrel as they may reach the same level of ADP inhibition as those exposed to prasugrel. 
This observation, along with widespread variability in platelet inhibitory response to clopidogrel, 
suggests that assessment of platelet function using drug specific reagents should inextricably be 
included in studies evaluating relationship between antiplatelet drugs and clinical endpoints such 
as bleeding outcome[3]. According to predefined ADP test value cutoff’s (uniformly applicable 
to patients exposed to either clopidogrel or prasugrel)[4] it would be possible to stratify patients 
in regard to bleeding risk. In addition to, recovery of platelet function following drug 
discontinuation could be quantified by serial platelet function testing and once platelet function 
outgrows predefined cutoff value that delineates bleeding tendency it would be safe to proceed 
with surgery regardless the number of days following drug cessation. This personalized approach 
may shorten waiting time and optimize bleeding and transfusion outcomes at the same time. 
Notably, for patients receiving dual antiplatelet therapy preoperatively, the role of aspirin should 
not be underestimated as it is well known that dual antiplatelet therapy provides more potent 
aspirin inhibitory effect[6], which in turn enhances the risk of bleeding attributable to aspirin 
effect[7]. Therefore, it seems reasonable to perform drugs specific platelets function testing using 
both ADP as well as arachidonic acid induced platelet function agonists. 
We congratulate authors for timely and elegant study. Further studies evaluating the relationship 
between preoperative antiplatelet therapy management and bleeding outcomes should use 
standardized way in defining clinical endpoints[2] and should inevitably include drug specific 
platelet function testing  as it may provide better understanding on the platelet inhibitory effect of 
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